An efficient deletion mutant packaging system for defective herpes simplex virus vectors: potential applications to human gene therapy and neuronal physiology.
Open Access
- 1 November 1990
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 87 (22) , 8950-8954
- https://doi.org/10.1073/pnas.87.22.8950
Abstract
We have previously described a defective herpes simplex virus (HSV-1) vector system that permits the introduction of virtually any gene into nonmitotic cells. pHSVlac, the prototype vector, stably expresses Escherichia coli beta-galactosidase from a constitutive promoter in many human cell lines, in cultured rat neurons from throughout the nervous system, and in cells in the adult rat brain. HSV-1 vectors expressing other genes may prove useful for studying neuronal physiology or performing human gene therapy for neurological diseases, such as Parkinson disease or brain tumors. A HSV-1 temperature-sensitive (ts) mutant, ts K, has been used as helper virus; ts mutants revert to wild type. In contrast, HSV-1 deletion mutants essentially cannot revert to wild type; therefore, use of a deletion mutant as helper virus might permit human gene therapy with HSV-1 vectors. We now report an efficient packaging system for HSV-1 vectors using a deletion mutant, D30EBA, as helper virus; virus is grown on the complementing cell line M64A. pHSVlac virus prepared using the deletion mutant packaging system stably expresses beta-galactosidase in cultured rat sympathetic neurons and glia. Both D30EBA and ts K contain a mutation in the IE3 gene of HSV-1 strain 17 and have the same phenotype; therefore, changing the helper virus from ts K to D30EBA does not alter the host range or other properties of the HSV-1 vector system.This publication has 35 references indexed in Scilit:
- Infection of cultured central nervous system neurons with a defective herpes simplex virus 1 vector results in stable expression of Escherichia coli beta-galactosidase.Proceedings of the National Academy of Sciences, 1990
- Expression of the E. coli Lac Z gene from a defective HSV-1 vector in various human normal, cancer-prone and tumor cellsFEBS Letters, 1989
- Progress Toward Human Gene TherapyScience, 1989
- Grafting Genetically Modified Cells to the Damaged Brain: Restorative Effects of NGF ExpressionScience, 1988
- The DNA Sequences of the Long Repeat Region and Adjoining Parts of the Long Unique Region in the Genome of Herpes Simplex Virus Type 1Journal of General Virology, 1988
- A Defective HSV-1 Vector Expresses Escherichia coli β-Galactosidase in Cultured Peripheral NeuronsScience, 1988
- Biology of gliomas: heterogeneity, oncogenes, growth factors.1986
- Complete DNA sequence of the short repeat region in the genome of herpes simplex virus type 1Nucleic Acids Research, 1986
- Expression of an immediate early polypeptide and activation of a viral origin of DNA replication in cells containing a fragment of herpes simplex virus DNAVirology, 1985
- Construction of a retrovirus packaging mutant and its use to produce helper-free defective retrovirusCell, 1983